Global X Cloud Computing ETF (NASDAQ: CLOU)

Dernières nouvelles pour Global X Cloud Computing ETF (NASDAQ:CLOU)

Technology

Communication Services

Real Estate

Consumer Cyclical

Healthcare

The Fund invests at least 80 percent of its total assets in the securities of the Indxx Global Cloud Computing Index (Underlying Index) and in American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs) based on the securities in the Underlying Index. The Fund's 80 percent investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed. The Fund may lend securities representing up to one-third of the value of the Funds total assets (including the value of the collateral received).

Wix.com Ltd

Sps Commerce Inc

Box Inc

Digital Realty Trust Inc.

Procore Technologies Pp

Zscaler Inc

Dropbox Inc. Class A

Paycom Software Inc.

Akamai Technologies Inc.

C3 Ai Inc A

Twilio Inc. Class A

Snowflake Computing Inc

Shopify Inc.

Hubspot Inc

Salesforce Inc.

Qualys Inc

Zoom Video Communications Inc. Class A

Workday, Inc., Class A

Global X Cloud Computing ETF

Cloud - United States Dollar

Cloud DX Inc

Cloud Nine Web3 Technologies Inc

CLOUD3 VENTURES INC by CLOUD3 VENTURES INC

Cloud3 Ventures Inc

Cloud3 Ventures Inc Ordinary Shares (Sub Voting)

CloudMD Software & Services Inc Ordinary Shares

Cloudastructure, Inc. - Class A Common Stock

Cloudastructure Inc

CLOUDBREAK DISCOVERY PLC by Cloudbreak Discovery PLC

Cloudbreak Discovery PLC

Cloudflare Inc

Cloudweb Inc

Clough Global Dividend and Income Fund Common Shares of beneficial interest

Clough Global Dividend and Income Fund

Clough Global Equity Fund Clough Global Equity Fund Common Shares of Beneficial Interest

Clough Global Equity Fund

Clough Global Opportunities Fund Common Stock

Clough Global Opportunities Fund

Rivals generally don't provide aid to each other, although in an indirect way, cruise ship operator Carnival Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) may be on the cusp of receiving residual benefits from its key competitor. Just recently, Royal Caribbean Cruises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) posted its <a href="https://www.benzinga.com/movers-shakers/25/04/45066484/royal-caribbean-cruises-q1-benefits-from-strong-demand-stock-surges">first-quarter fiscal 2025 earnings</a> report and overall, the results were quite encouraging. It may be just what the CCL stock needs to find its footing following a rough outing so far this year.
On the top line, Royal Caribbean posted $4 billion, implying sales growth of 7.2% on a year-over-year basis. This figure only marginally missed the analysts' consensus target of $4.01 billion — not a bad showing considering the deflated macro environment, particularly in terms of <a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">consumer sentiment</a>. Notably, passenger ticket revenues rose 7.9% year-on-year to $2.74 billion, while cruise operating expenses ticked up to $2.07 billion from $2.05 billion a year ago.
Royal Caribbean CEO Jason Liberty remarked that the company is navigating "the complexities of the current macroeconomic landscape" while implementing solutions to optimize revenue and manage costs.
Following the disclosure, RCL popped sharply higher during the premarket session. However, in the early hours of the open market session, the equity was volatile. Nevertheless, the core fundamental argument is that Royal's results may be signifying a <a href="https://www.benzinga.com/news/25/04/45071496/whats-going-on-with-carnival-stock-following-royal-caribbean-earnings">return of consumer demand</a> along with pricing power in the cruise industry.
<h2 class="wp-block-heading">Looking At The True Demand Profile Of CCL Stock</h2>
While the recent headlines deliver much-needed encouragement for Carnival investors, the reality is that it's one piece of a much bigger puzzle. At the most elemental level, the market makes a decision for any given time period whether to be a net buyer of CCL stock or not. This impetus, the trigger to transition from an observer to a buyer, is demand.
What makes demand such a compelling statistic is its binary nature. Unlike price, which is a continuous scalar signal (meaning that it theoretically extends into infinity), demand has boundaries. Demand is defined or discrete. By logical deduction, demand is either happening or it's not happening — there are no half-demand states.
Thanks to this fundamental attribute, demand represents one of the few metrics that can be meaningfully measured across sentiment regimes. In other words, prices often change over decades but the impetus to buy (or not to buy) largely remains the same: when a security is purchased, it's reasonable to assume that whatever was contextually meaningful at the point of transaction triggered the greed component of the fear-greed spectrum.
Using Markovian principles of probabilistic logic, these demand triggers can be quantified and categorized for empirical analysis. Specific to CCL stock, the security printed in the past 10 weeks a "4-6" sequence: four up weeks interspersed with six down weeks, with a negative trajectory across the period.
Generally, when this sequence flashes, the odds of upside success in the subsequent week (which corresponds with the business week beginning April 28) is around 55.1%, giving the bulls a slight edge. No, it's not a game-changing shift in the probabilities. However, in the prior 30 weeks leading up to the last-10-week period, the demand profile was up week dominant, 18 weeks up to 12 weeks down.
In other words, the last 10 weeks, with their bearishly dominated profile, may have been a brief corrective spell. Moving forward, it's quite possible that the bulls may attempt to take control.
<h2 class="wp-block-heading">Strategizing for the Potential Upswing</h2>
Forecasting isn't an exact science obviously. That said, based on empirical data projected forward, there's a possibility that CCL stock can drive above the $19.40 level, perhaps touch $19.50 over the next two to three weeks. With that in mind, the most aggressive multi-leg options strategy arguably available that's within the realm of rationality is the 18.50/19.50 bull call spread expiring May 16.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29150958/CCL-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-893645" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29150958/CCL-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29150958/CCL-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29150958/CCL-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29150958/CCL-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
The above transaction involves buying the $18.50 call and simultaneously selling the $19.50 call, for a net debit paid of $50. Should CCL stock rise through the short strike price at expiration, the maximum reward stands at $50, a nice payout of 100%.
What makes this option strategy particularly sweet is twofold. First, the high payout implies that the market makers believe the odds of success are unfavorable. Nevertheless, the actual demand profile and empirical probabilities suggest otherwise. Second, implied volatility is several ticks lower than historic volatility, suggesting a lower overall premium to cover the risk of unexpected kinesis.
Bottom line? Wall Street right now appears to be discounting the idea that CCL stock can recover. This can be an intriguing contrarian opportunity, especially because it's offered at a relative discount.
Read next:
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/45069781/trumps-first-100-days-what-he-delivered-where-he-fell-short-how-markets-reacted">Trump&#8217;s First 100 Days: What He Delivered, Where He Fell Short, How Markets Reacted</a></li>
</ul>
Photo: Shutterstock

Earnings

Equities

Long Ideas

Options

Options Corner: Carnival Could Be Setting Sail Toward A Contrarian Comeback

Logitech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) reported quarterly earnings of $0.93 per share which beat the analyst consensus estimate of $0.86 by 8.14 percent. This is a 6.06 percent decrease over earnings of $0.99 per share from the same period last year. The company reported quarterly sales of $1.01 billion which missed the analyst consensus estimate of $1.02 billion by 1.44 percent. This is a 0.10 percent decrease over sales of $1.01 billion the same period last year.

Earnings Beats

Earnings Misses

News

LOGI

Logitech International Q4 Adj. EPS $0.93 Beats $0.86 Estimate, Sales $1.01B Miss $1.02B Estimate

First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) lowers FY2025 GAAP EPS guidance from $17.00-$20.00 to $12.50-$17.50 vs $18.20 analyst estimate. Lowers FY2025 sales outlook from $5.30 billion-$5.80 billion to $4.50 billion-$5.50 billion vs $5.46 billion estimate.

Guidance

FSLR

First Solar Lowers FY2025 GAAP EPS Guidance from $17.00-$20.00 to $12.50-$17.50 vs $18.20 Est; Lowers FY2025 Sales Guidance from $5.30B-$5.80B to $4.50B-$5.50B vs $5.46B Est

Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.16) by 237.5 percent. This is a 26.03 percent increase over losses of $(0.73) per share from the same period last year. The company reported quarterly sales of $2.79 billion which met the analyst consensus estimate. This is a 1.90 percent increase over sales of $2.74 billion the same period last year.

Caesars Entertainment Q1 EPS $(0.54) Misses $(0.16) Estimate, Sales $2.79B Inline

Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.24) by 37.5 percent. The company reported quarterly sales of $26.58 million which missed the analyst consensus estimate of $30.83 million by 13.79 percent. This is a 42.88 percent decrease over sales of $46.53 million the same period last year.

ZYXI

Zynex Q1 EPS $(0.33) Misses $(0.24) Estimate, Sales $26.58M Miss $30.83M Estimate

AEYE

AudioEye Q1 Adj. EPS $0.15 Up From $0.08 YoY, Sales $9.73M Beat $9.71M Estimate

Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Civeo to report an earnings per share (EPS) of $-0.41.
Investors in Civeo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.96, leading to a 2.27% drop in the share price on the subsequent day.
Here's a look at Civeo's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.14</td>
<td>-0.02</td>
<td>0.21</td>
<td>-0.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.10</td>
<td>-0.36</td>
<td>0.56</td>
<td>-0.23</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>2.0%</td>
<td>4.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745957016_0.png" alt="eps graph" />
<h3>Civeo Share Price Analysis</h3>
Shares of Civeo were trading at $20.09 as of April 28. Over the last 52-week period, shares are down 16.55%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Observations about Civeo</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Civeo.
Civeo has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $28.0, the consensus suggests a potential 39.37% upside.
<h3>Peer Ratings Overview</h3>
The analysis below examines the analyst ratings and average 1-year price targets of and Civeo, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<h3>Summary of Peers Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for and Civeo, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Civeo</td>
<td>Buy</td>
<td>-11.62%</td>
<td>$28.11M</td>
<td>-5.81%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Civeo is positioned at the bottom among its peers based on consensus rating. It ranks at the bottom for revenue growth, showing a decline of 11.62%. In terms of gross profit, Civeo's performance is weak compared to its peers. Additionally, its return on equity is negative at -5.81%, indicating lower profitability compared to others in the group.
<h3>Discovering Civeo: A Closer Look</h3>
Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia and the United States. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, Australia and the United States.
<h3>Civeo: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Civeo's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -11.62%. This indicates a decrease in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -9.98%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Civeo's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -5.81%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.41%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.21, Civeo adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/CVEO/earnings">To track all earnings releases for Civeo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVEO

Civeo's Earnings Outlook

Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) reported quarterly earnings of $2.02 per share which beat the analyst consensus estimate of $1.85 by 9.19 percent. This is a 260.71 percent increase over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $2.20 billion which missed the analyst consensus estimate of $2.52 billion by 12.84 percent. This is a 103.15 percent increase over sales of $1.08 billion the same period last year.

Expand Energy Q1 Adj. EPS $2.02 Beats $1.85 Estimate, Sales $2.20B Miss $2.52B Estimate

Haverty Furniture Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HVT#NYSE">HVT</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Haverty Furniture Cos will report an earnings per share (EPS) of $0.16. 
Anticipation surrounds Haverty Furniture Cos's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.32 in the last quarter, leading to a 9.06% increase in the share price on the following day.
Here's a look at Haverty Furniture Cos's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.17</td>
<td>0.47</td>
<td>0.17</td>
<td>0.36</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.49</td>
<td>0.29</td>
<td>0.27</td>
<td>0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>-7.000000000000001%</td>
<td>1.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745957002_0.png" alt="eps graph" />
<h3>Market Performance of Haverty Furniture Cos's Stock</h3>
Shares of Haverty Furniture Cos were trading at $18.32 as of April 28. Over the last 52-week period, shares are down 40.86%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/HVT/earnings">To track all earnings releases for Haverty Furniture Cos visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Haverty Furniture Cos's Earnings Preview

Big 5 Sporting Goods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGFV#NASDAQ">BGFV</a>) is looking for Q2 GAAP EPS of $(0.90)-$(0.75)..

BGFV

Big 5 Sporting Goods Sees Q2 GAAP EPS $(0.90)-$(0.75)

First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) reported quarterly earnings of $1.95 per share which missed the analyst consensus estimate of $2.63 by 25.86 percent. This is a 11.36 percent decrease over earnings of $2.20 per share from the same period last year. The company reported quarterly sales of $844.57 million which beat the analyst consensus estimate of $839.28 million by 0.63 percent. This is a 6.35 percent increase over sales of $794.11 million the same period last year.

First Solar Q1 EPS $1.95 Misses $2.63 Estimate, Sales $844.57M Beat $839.28M Estimate

NCS Multistage Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCSM#NASDAQ">NCSM</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate NCS Multistage Holdings to report an earnings per share (EPS) of $0.64.
Investors in NCS Multistage Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Here's a look at NCS Multistage Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td>1.27</td>
<td>-1.23</td>
<td>-0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.27</td>
<td>1.50</td>
<td>-1.03</td>
<td>0.99</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>2.0%</td>
<td>-1.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<h3>Tracking NCS Multistage Holdings's Stock Performance</h3>
Shares of NCS Multistage Holdings were trading at $30.23 as of April 28. Over the last 52-week period, shares are up 69.2%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/NCSM/earnings">To track all earnings releases for NCS Multistage Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NCSM

Exploring NCS Multistage Holdings's Earnings Expectations

Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) is looking for Q1 Adj EPS of $0.50-$0.75 vs $0.59 analyst estimate. sees sales of $750.000 million-$800.000 million vs $756.37 million analyst estimate.

QRVO

Qorvo Sees Q1 Adj EPS $0.50-$0.75 vs $0.59 Est; Sees Sales $750.000M-$800.000M vs $756.37M Est

ExlService Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>) affirms FY2025 Adj EPS guidance from $1.83-$1.89 to $1.83-$1.89 vs $1.87 analyst estimate. Raises FY2025 sales outlook from $2.02 billion-$2.06 billion to $2.04 billion-$2.06 billion vs $2.05 billion estimate.

EXLS

ExlService Hldgs Affirms FY2025 Adj EPS Guidance of $1.83-$1.89 vs $1.87 Est; Raises FY2025 Sales Guidance from $2.02B-$2.06B to $2.04B-$2.06B vs $2.05B Est

Unifi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Unifi will report an earnings per share (EPS) of $-0.60.
Anticipation surrounds Unifi's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.31, leading to a 10.1% drop in the share price on the subsequent day.
Here's a look at Unifi's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.55</td>
<td>-0.25</td>
<td>-0.21</td>
<td>-0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.86</td>
<td>-0.42</td>
<td>-0.22</td>
<td>-0.57</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>-11.0%</td>
<td>17.0%</td>
<td>16.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745956974_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Unifi were trading at $5.35 as of April 28. Over the last 52-week period, shares are down 10.89%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/UFI/earnings">To track all earnings releases for Unifi visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Unifi's Earnings

Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) reported quarterly earnings of $1.42 per share which beat the analyst consensus estimate of $1.00 by 42 percent. This is a 2.16 percent increase over earnings of $1.39 per share from the same period last year. The company reported quarterly sales of $869.50 million which beat the analyst consensus estimate of $850.39 million by 2.25 percent. This is a 7.70 percent decrease over sales of $941.99 million the same period last year.

Qorvo Q4 Adj. EPS $1.42 Beats $1.00 Estimate, Sales $869.50M Beat $850.39M Estimate

BBIO

BridgeBio Pharma Q1 EPS $(0.88) Beats $(0.97) Estimate, Sales $116.60M Beat $61.94M Estimate

-- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 --
-- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with the anti-TL1A drug class --
-- XmAb942 half-life supports a 12-week maintenance dosing interval in XENITH-UC --
-- Lead selection for XmAb TL1A x IL23p19 program on track for first-in-human study start in 2026 --
-- Management hosting webcast and conference call at 5:00 p.m. ET / 2:00 p.m. PT today --
Xencor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942, a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD). Interim results from the healthy volunteer dose-escalation study indicate that XmAb942 is well tolerated at single and multiple doses. Pharmacokinetic analysis of the single dose cohorts estimates a human half-life of greater than 71 days for XmAb942, which supports a 12-week dosing interval during maintenance treatment.
Based on these positive interim results, Xencor is initiating the XENITH clinical program, advancing XmAb942 into a Phase 2b study in patients with moderate-to-severely active UC (XENITH-UC), with the expected study start in the second half of 2025.
Lead selection for Xencor's XmAb TL1A x IL23p19 bispecific antibody continues to advance. New in vitro studies show that several lead candidates match the target inhibition potency of commercial monospecific antibodies, but in a simple bispecific immunoglobulin G (IgG) format. Currently, these candidates are in final lead selection studies and manufacturing, in parallel, to prepare for the first-in-human study planned for 2026.
"Our Phase 1 data for XmAb942 validate our design goals for a best-in-class anti-TL1A therapy, combining high potency with less frequent dosing to potentially improve clinical outcomes and convenience for patients living with inflammatory bowel disease," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "We are excited to start our Phase 2b XENITH-UC trial later this year to efficiently support dose selection for pivotal studies, and we are poised to select our TL1A x IL23p19 bispecific lead candidate for an anticipated Phase 1 start in 2026. These and other milestones across our clinical portfolio are supported by our strong cash position."
Key Highlights From Phase 1 Study Interim Results
The Phase 1 study of XmAb942 in healthy volunteers is a randomized, double-blind, placebo-controlled, dose-escalation trial, exploring intravenous (IV) and subcutaneous (SC) dose administration, at three escalating dose levels. The interim results reflect analyses with subjects in single dose cohorts (IV, n=24; SC, n=24) and in multiple dose cohorts (IV, n=16).
<ul>
<li>Safety: The blinded interim safety analysis indicates that all dose levels and routes of administration of treatment were well tolerated. No serious adverse events were observed, and no adverse events led to discontinuation from the study. The study remains blinded until follow-up is completed for the multiple dose portion of the study.</li>
<li>Pharmacokinetics: The interim analysis of single dose cohorts produced a half-life estimate of greater than 71 days, which is in line with expectations from the 23-day half-life in non-human primates and scaling metrics for half-life extended antibodies.</li>
<li>Pharmacodynamics: Consistent with XmAb942's high-potency and extended exposure design, large and durable dose-dependent increases of total TL1A in circulation were observed in both IV and SC cohorts. Circulating free TL1A was reduced significantly compared to placebo for all cohorts.</li>
<li>Immunogenicity: Early pharmacokinetic analysis of single and multiple dose cohorts shows no apparent evidence of anti-drug antibodies emerging against XmAb942.</li>
</ul>
XENITH-UC: Phase 2b Study in Ulcerative Colitis (UC)
The Phase 2b study of XmAb942 in UC (XENITH-UC) will be a randomized, double-blind, placebo-controlled trial in patients with moderate-to-severely active UC, whose disease has progressed after at least one conventional or advanced therapy. XmAb942 will be administered intravenously during the 12-week induction period and subcutaneously every 12 weeks during the maintenance period. The primary endpoint of the study will be clinical remission based on the modified Mayo score at week 12. The study is designed to enroll approximately 220 patients across three induction dose levels and powered to enable Phase 3 dose selection. XENITH-UC is expected to start in the second half of 2025.

Biotech

General

XNCR

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study Of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody For Treatment Of Inflammatory Bowel Disease

AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.23) by 39.13 percent. This is a 44 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $123.62 million which beat the analyst consensus estimate of $122.92 million by 0.57 percent. This is a 13.57 percent increase over sales of $108.85 million the same period last year.

ATRC

AtriCure Q1 Adj. EPS $(0.14) Beats $(0.23) Estimate, Sales $123.62M Beat $122.92M Estimate

Onity Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONIT#NYSE">ONIT</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Onity Group to report an earnings per share (EPS) of $1.87.
The announcement from Onity Group is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company missed EPS by $0.22, leading to a 0.92% drop in the share price the following trading session.
Here's a look at Onity Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.35</td>
<td>1.27</td>
<td>1.36</td>
<td>1.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.13</td>
<td>2.65</td>
<td>1.33</td>
<td>3.74</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>0.0%</td>
<td>-9.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745956944_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Onity Group were trading at $34.34 as of April 28. Over the last 52-week period, shares are up 45.18%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/ONIT/earnings">To track all earnings releases for Onity Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Global X Cloud Computing ETF

Actualités

Dernières nouvelles pour Global X Cloud Computing ETF (NASDAQ:CLOU)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL